While I’m not at #ASCO22 this year, there are some very interesting and practical #radonc related abstracts. I’ve summarized and stitched them together here. What did I miss @jryckman3? @ASCO@JCO_ASCO
SBRT for primary kidney cancer is an emerging option for non-surgical patients. I’m grateful to have worked on this with @ChadTangMD. More to come as we explore potential application of MR-Linac. @ACKoongMDPhD@PrajnanDasMD @cd_fuller
#AdvancesRO article in press: SBRT for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison with Surgery, Tumor Ablation, and Observation https://t.co/nzS2q5Njqv #OpenAccess#radonc